Name:

Stef Meers

Date of Birth:

29 February 1976

Place of Birth:

Hasselt, Belgium

Nationality:

Belgian

Home Address:

Langveld 1/0002

2600 Berchem (Antwerp)

BELGIUM

Work Address:

Medical licence number:

Department of Hematology/Oncology

AZ Klina

Augustijnslei 100

2930 Brasschaat

BELGIUM

Telephone: +32 3 650 52 93 or +32 3 650 50 52

Fax:           +32 3 650 50 93

E-mail:       stef.meers@klina.be

1-19201-12-598

1994-1997:

Medical School, University of Leuven
Preclinical years: magna cum laude

1997-2001:

Medical School, University of Leuven

Clinical years: summa cum laude

2001-2003:

2003-2007:

Training in Internal Medicine

PhD training Laboratory of Experimental Hematology/Stem Cell Institute, University of Leuven. Promoter: prof.dr. Michel Delforge. Grant of Research Foundation Flanders (FWO-Vlaanderen)

2007-2009:

Specialization: Hematology and Hemato-Oncology

University Hospital Leuven. Director: Prof.dr. GE Verhoef

7/2008:

PhD Medical Sciences University of Leuven, Belgium

“Activated lymphocytes and monocytes in myelodysplastic syndromes”

2003-2005:

2007-2008:

1/2009 – 6/2010

Clinical residency in internal medicine in AZ Klina, Brasschaat (B) and AZ Sint-Augustinus, Wilrijk (B)

Clinical residency in hematology in University Hospital Leuven. Director: prof. Dr. GE Verhoef

Staff member, Hematology Department, University Hospital of Leuven, Belgium

Since 7/2010

Hematologist, Iridium Cancer Network

AZ Klina, Brasschaat, Belgium

AZ St-Augustinus, Wilrijk, Belgium

Belgian Hematological Society (BHS)

European Hematology Association (EHA)

2006:

Poster award of Belgian Society of Hematology

2007:

Amgen award for best presentation of Belgian Society of Hematology

Meers S., Kasran A., Boon L., Lemmens J., Ravoet C., Boogaerts M., Verhoef G., Verfaillie C., Delforge M. Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells. Leukemia 2007;21:2411-2419

Meers S., Vandenberghe P., Boogaerts M., Verhoef G., Delforge M. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. Leuk Res 2008;32(7):1026-1035.

Meers S., Boon L., Verhoef G., Delforge M. Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide. Am J Hematol 2009;84(11):769-70.

Maertens J., Maertens V., Theunissen K., Meersseman W., Meersseman P., Meers S., Verbeken E., Verhoef G., Van Eldere J., Lagrou K. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009;49(11):1688-93

Meers S., Delforge M., Verhoef G. The immune system in myelodysplastic syndromes: a target for therapy? Ned Tijdschr Hematol 2010;7:9-16

Meers S., Lagrou K., Theunissen K., Dierickx D., Delforge M., Devos T., Janssens A., Meersseman W., Verhoef G., Van Eldere J., Maertens J. Myeloablative conditioning predisposes for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin Infect. Dis 2010 April